Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

Nan Bi
Nan Bi
Shixiu Wu
Shixiu Wu
Changxing Lv
Changxing Lv
Anhui Shi
Anhui Shi
Wei Jiang
Wei Jiang
Yaping Xu
Yaping Xu
Jingbo Wang
Jingbo Wang

BMC Cancer, pp. 1-10, 2020.

Cited by: 0|Bibtex|Views29|Links
WOS
Keywords:
Locally advanced Non-small-cell lung cancer ECOG 2 Chemoradiotherapy EfficacyMore(1+)

Abstract:

There is no consensus on the therapeutic approach to ECOG 2 patients with locally advanced non-small-cell lung cancer (LA-NSCLC), despite the sizable percentage of these patients in clinical practice. This study focused on the efficacy, toxicity and the optimal chemotherapy regimen of CCRT in ECOG 2 patients in a phase III trial. Patients...More

Code:

Data:

Your rating :
0

 

Tags
Comments